Inventiva Announces Trading Resumption on Euronext Paris
Daix, France – Inventiva (Euronext Paris and Nasdaq: IVA) announced the resumption of trading for its ordinary shares on Euronext Paris, effective 4:30 p.m. CET. This decision follows a temporary halt in trading initiated by the company, aimed at facilitating its recently announced public offering.
Trading had been paused on November 13, at 9:00 a.m. CET, to finalize investor allocations and disclose pricing details for the American Depositary Shares, each corresponding to one new ordinary share of the company, with a nominal value of €0.01.
About Inventiva
Inventiva is a dedicated biopharmaceutical company focused on the creation and advancement of oral therapies for metabolic dysfunction-associated steatohepatitis (MASH). One of the company's key products, lanifibranor, is currently undergoing evaluation in the NATiV3 pivotal Phase 3 clinical trial, designed for adult patients suffering from MASH, known for being a prevalent and progressive chronic liver disease.
Investing in Innovating Treatments
Listed on Euronext Paris as IVA and also on Nasdaq, Inventiva is committed to creating solutions that significantly improve the quality of life for patients with chronic diseases. The company’s investments in research and development are rooted in a strong commitment to innovation and addressing unmet medical needs. This focus positions Inventiva as a promising player in the biopharmaceutical landscape, particularly in the context of MASH, which affects millions globally.
Recent Developments
Recent studies and advancements indicate a resolute path ahead for Inventiva. The NATiV3 trial results are eagerly anticipated, as they hold the potential to elevate the visibility of lanifibranor and further bolster the company’s portfolio. Positive outcomes from these trials could possibly lead to an expanded market presence and improved investor confidence.
Company Leadership and Strategy
Under the strategic guidance of Pascaline Clerc, EVP of Strategy and Corporate Affairs, Inventiva is navigating the complexities of pharmaceutical development with a focus on sustainable growth and innovation. The team's expertise is crucial for ensuring the successful development and market introduction of their pipeline products.
Contact Information
Inventiva
Pascaline Clerc
EVP, Strategy and Corporate Affairs
Email: media@inventivapharma.com
Phone: +1 202 499 8937
ICR Healthcare Media Relations
Alexis Feinberg
Email: inventivapr@icrhealthcare.com
Phone: +1 203 939 2225
ICR Healthcare Investor Relations
Patricia L. Bank
Email: patti.bank@icrhealthcare.com
Phone: +1 415 513 1284
Frequently Asked Questions
What is the significance of the trading resumption for Inventiva?
The resumption indicates a new phase for Inventiva as it moves forward with its public offering and seeks further investments for growth.
What therapies is Inventiva currently developing?
Inventiva is mainly focused on therapies for metabolic dysfunction-associated steatohepatitis (MASH), particularly the novel drug lanifibranor.
Where is Inventiva publicly listed?
Inventiva is listed on Euronext Paris under the ticker IVA and also on the Nasdaq Global Market.
Who is involved in Inventiva's corporate affairs?
Pascaline Clerc, as EVP of Strategy and Corporate Affairs, plays a key role in steering the company’s direction.
How can I get in touch with Inventiva for more information?
You can reach Inventiva through the provided email addresses for media and investor relations for inquiries.